This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Feb. 4, 2013 /PRNewswire/ -- Medbox, Inc. (OTC Markets: MDBX) (
www.medboxinc.com), announced that they have initiated a program through their public education division that will engage in an informational campaign featuring printed literature to be distributed to future retail marijuana establishments as well as online support services through a website. The theme of the informational literature and website will be a "responsible consumption" campaign that Medbox believes is a necessary educational component in the post-prohibition marijuana era in the states of
Washington. As mentioned in a prior press release, the entity will also offer free expertise to newly adopted recreational marijuana states on how to create systems, procedures, and regulations that provide the utmost in legal compliance, accountability and transparency.
"Now that some states have chosen to view marijuana as they would alcohol, the correct plan of action needs to evolve around understanding the plant and educating the public about the positive and negative effects while under the influence of the drug," stated
Vincent Mehdizadeh, Founder and Senior Consultant at Medbox, Inc. "Whether you are for or against the recreational use of marijuana, the reality is that the voters in two states have spoken and systems to control and tax the drug, like the products Medbox offers, are more relevant than ever before. Similarly, educating the public should be a focus for companies like Medbox that are taking a leadership role in the maturation period of this burgeoning industry."
In other news, the company announced that they have signed term sheets with two noteworthy and very relevant bio-tech companies in vertical industries parallel to Medbox. The deals have evolved into draft definitive agreement status whereas the target companies are in the midst of revising contract language therein. The companies are all bound by a non-disclosure component to the executed term sheets so details will be made available to the public as soon as the same can be legally disseminated. The company also announced that they are in talks with several other companies that offer ancillary products and services to the retail pharmaceutical and marijuana industries.